Characteristics of subjective cognitive decline associated with amyloid positivity

• DOI: 10.1002/alz.12512
• Publication Date: 2021-12-08T09:11:35Z
• Authors: Olin Janssen; Willemijn J. Jansen; Stephanie J.B. Vos; Merce Boada; Lucilla Parnetti; Tomasz Gabryelewicz; Tormod Fladby; José Luis Molinuevo; Sylvia Villeneuve; Jakub Hort; Stéphane Epelbaum; Alberto Lleó; Sebastiaan Engelb...; Wiesje M. van der...; Susan Landau; Julius Popp; Anders Wallin; Philip Scheltens; Marcel Olde Rikkert; Peter J. Snyder; Chris Rowe; Gaël Chételat; Agustin Ruíz; Marta Marquié; Elena Chipi; Steffen Wolfsgruber; Michael Heneka; Henning Boecker; Oliver Peters; Jonas Jarholm; Lorena Rami; Adrià Tort‐Merino; Alexa Pichet Binette; Judes Poirier; Pedro Rosa‐Neto; Jiri Cerman; Bruno Dubois; Marc Teichmann; Daniel Alcolea; Juan Fortea; M. Belén Sánchez‐...; Jarith Ebenau; Cornelia Pocnet; Marie Eckerström; Louisa Thompson; Victor Villemagne; Rachel Buckley; Samantha Burnham; Marion Delarue; Yvonne Freund‐Levi; Åsa K. Wallin; Inez Ramakers; Magda Tsolaki; Hilkka Soininen; Harald Hampel; Luiza Spiru; ; ; ; Betty Tijms; Rik Ossenkoppele; Frans R. J. Verhey; Frank Jessen; Pieter Jelle Visser
• Keywords: PRECLINICAL ALZHEIMERS-DISEASE; Positron emission tomography; Amyloid; SYMPTOMS; positron emission tomography; Humans; Amyloid; Amyloidogenic Proteins; Amyloidosis; Apolipoprotein E4/genetics; Biomarkers; Brain/metabolism; Cognitive Dysfunction/genetics; Cognitive Dysfunction/psychology; Positron-Emission Tomography; Alzheimer's disease; amyloid; cerebrospinal fluid; positron emission tomography; subjective cognitive decline; Apolipoprotein E4; 610; Amyloidogenic Proteins; cerebrospinal fluid; 03 medical and health sciences; 0302 clinical medicine; Humans; Cognitive Dysfunction; ddc:610; DEPOSITION; OLDER-ADULTS; genetics [Apolipoprotein E4]; POPULATION; RISK; ddc:610; Featured Articles; DEMENTIA; genetics [Cognitive Dysfunction]; amyloid; Brain; Amyloidosis; Alzheimer's disease; PREVALENCE; COMMUNITY; Cerebrospinal fluid; metabolism [Brain]; Positron-Emission Tomography; Subjective cognitive decline; Human medicine; psychology [Cognitive Dysfunction]; subjective cognitive decline; MEMORY COMPLAINTS; Biomarkers

AbstractIntroductionThe evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited.MethodsIn 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD‐specific characteristics (informant confirmation, domain‐specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity.ResultsBetween cohorts, amyloid positivity in 70‐year‐olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant‐confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages.DiscussionNext to age, setting, and APOE ε4 carriership, SCD‐specific characteristics may facilitate the identification of amyloid‐positive individuals.